Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Composite preparation applied to antiviral treatments of HIV, HBV and nCoV

A compound preparation and antiviral technology, applied in the field of medicine, can solve the problems of high price and narrow adaptability of antiviral drugs, and achieve the effects of improving immunity, wide applicability and low cost.

Inactive Publication Date: 2021-01-01
盛晓春
View PDF1 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] The purpose of the present invention is to solve the problem that antiviral drugs are generally expensive and have narrow adaptability in the prior art, and propose a new type of extremely fast, effective and low-cost comprehensive antiviral compound preparation. The technology achieved is briefly described below Effect

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Composite preparation applied to antiviral treatments of HIV, HBV and nCoV
  • Composite preparation applied to antiviral treatments of HIV, HBV and nCoV
  • Composite preparation applied to antiviral treatments of HIV, HBV and nCoV

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0021] Experimental purpose: the compound preparation is used for antiviral treatment of HIV virus.

[0022] Experimental population: 180 HIV-1 infected persons aged 30-40, including 90 male infected persons and 90 female infected persons, 90 persons in each group.

[0023] The HIV-1 RNA quantitative detection average value of infected persons is: the HIV-1 RNA quantitative detection average value of the first group is 5.27E+2, and the HIV-1 RNA quantitative detection average value of the second group is 5.23E+2.

[0024] Drugs: Plan 1 uses placebo with other antiretroviral drugs;

[0025] Scheme 2 uses the compound preparation of the present invention and the same antiretroviral drugs as in Scheme 1.

[0026] Medication cycle: 24 weeks.

[0027] Experimental method: the first group of infected people took the medicine in scheme 1, and the second group of infected people took the medicine in scheme 2.

[0028] Experimental results: The average value of HIV-1 RNA quantitativ...

Embodiment 2

[0031] Experimental purpose: to determine the inhibition of the compound preparation on HBV.

[0032] Subjects: 12 patients, including 6 male patients and 6 female patients, aged between 25 and 35, all of them are hepatitis B virus carriers.

[0033] The patient's condition: the value of hepatitis B virus DNA is 9.1E+2, the hepatitis B surface antigen is greater than 0.3ng / ml, the hepatitis B surface antibody is 460-480IU / L, the hepatitis B e antigen is 0.6-0.7PEIU / mL, and the hepatitis B e antibody is 1.02 -1.1PEIU / mL, hepatitis B core antibody is 1.3-1.5PEIU / mL, median of liver stiffness (KPA) is 12.3-13.4, median of fat decay (db / m) is 265-295, color Doppler ultrasound results are normal .

[0034] Experimental method: 3 male patients, male No. 1, male No. 2 and male No. 3, and 3 female patients, female No. 1, female No. 2 and female No. 3, were selected to take the compound preparation respectively for a period of 8 months. The unselected 3 male patients, male No. 4, mal...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention discloses a composite preparation applied to antiviral treatments of HIV, HBV and nCoV, and belongs to the technical field of medicines. The composite preparation comprises the following components in parts by mass: 6-10 parts of tenofovir disoproxil fumarate, 4-8 parts of nicotinamide mononucleotide and 4-8 parts of a green coffee bean extract. Firstly, chlorogenic acid andthe tenofovir disoproxil fumarate are used for down-regulating and inhibiting expression of nucleoproteins of viruses, meanwhile, the composite preparation induces cell apoptosis of the viruses, thenrepairs and replicates damaged health factors (namely repairs and replicates DNA) by the nicotinamide mononucleotide, finally proliferates immune cells of human body, can promote the human body to quickly generate the corresponding immune body constitution to resist the viruses, has an antiviral effect, can also can improve immunity of a user, is low in manufacturing cost and also wide in application range, and can be used for the antiviral treatments of the HIV, HBV and nCoV.

Description

technical field [0001] The invention relates to the technical field of medicine, in particular to a compound preparation applied to antiviral treatment of HIV, HBV and nCoV. Background technique [0002] AIDS is the abbreviation of Acquired Immunodeficiency Syndrome, which is a chronic infectious disease caused by Human Immunodeficiency Virus (HIV). The disease is mainly transmitted through sexual contact, blood and mother to child. HIV mainly invades and destroys CD4+ T lymphocytes, resulting in impairment or even defect of immune cells and (or) functions of the body, and eventually merges with various serious opportunistic infections and tumors. It has the characteristics of rapid spread, slow onset and high fatality rate. [0003] Hepatitis B virus is called hepatitis B virus for short. It is a DNA virus belonging to the family Hepadnaviridae. According to current knowledge, HBV is only susceptible to humans and orangutans, causing viral hepatitis B disease. The whol...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/675A61K31/706A61K31/216A61P31/18A61P31/20A61P31/14
CPCA61K31/675A61K31/706A61K31/216A61P31/18A61P31/20A61P31/14A61K2300/00
Inventor 盛晓春
Owner 盛晓春
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com